Rapid Reviews – II By Sudeep Gupta
Session 6: Rapid Reviews – II
Chairpersons :
Meenakshi Thakur, Asha Kapadia, Shekhar Salkar
Speaker :
Sudeep Gupta
1. Avelumab (MSB001071BC), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase lb JAVELIN solid tumor trial
Author: Dirix LY
Conference: SABCS
2. Importance of margin width and re-excision in breast conserving treatment of early breast cancer; a Danish Breast Cancer Cooperative Group study at 11,900 women
Author: Bodilsen A
Conference: SABCS
3. HER2 status as predictive marker for AI vs Tam benefit: a TRANS-AIOG meta-analysis of 12129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2
Author: Bartlett JMS
Conference: SABCS
4. Ten year follow-up of the BCIRG-006 trial comparing doxorubicin plus cycliphosphamide followed by docetaxel (ACT) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer patients.
Author: Slamon DJ
Conference: SABCS
5. Trastuzumab emtasine improves overall survival versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer: Final overall survival results from the phase 3 TH3RESA study
Author: Wildiers H
Conference: SABCS
6. Randomized phase 3 trial of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor positive, node positive early breast cancer: Final efficacy and safety results of the femara versus anastrozole clinical evaluation (Face) triall
Author: O’ Shaughanessy J
Conference: SABCS
7. NEO-EXCEL phase III neoadjuvant trial of pre-operative exemstane or letrozole +/ celecoxib in the treatment of ER positive postmenopausal early breast cancer
Author: Francis A
Conference: SABCS
8. Final results of a first-in-human phase I study of the tamoxifen (TAM) metabolite, Z-Endoxifen hydrochloride (Z—Endx) in women with aromatase inhibitor (AI) refractory metastatic breast cancer (MBC) (NCT01327781)
Author: Goetz MP
Conference: SABCS
9. HER A trial: 10 years follow up of trastuzumab after adjuvant chemotherapy in HER2 positive early breast cancer – Final analysis
Author: Jackisch C
Conference: SABCS
10. The survival benefit offered by the surgical management of low-grade ductal carcinoma in situ o f the breast
Author: Y. Sagara
Conference: ASCO
11. Recurrence rates for ductal carcinoma in situ: Analysis of 2,996 patients treated wth breast conserving surgery over 30 years
Author: Kimberly J. Van Zee
Conference: ASCO Breast Symposium
12. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/ Alliance/ ECOG ACRIN/ NCIC Clinical Trials Group/ NRG Oncology study S0307
Author: J. Gralow
Conference: ASCO
Effect of regular exercise on survival in women with early stage luminal-a breast cancer
Author: O. Yazici
Conference: ESMO
14. Short and Long-term Toxicity and Cosmesis After Interstital Multicatheter Brachytherapy for Accelerated Partial Breast Irradiation: A Multi-Institutional Study
Robert Kuske
Conference: ASTRO
15. 241: Impact of Ipsilateral Blood Pressure Measurements, Blood Draws, Infusions, and Air Travel on the Risk of Lymphedema forPatients Treated for Breast Cancer: A Prospective Study
Author:Alphonse Taghian
Conference: ASTRO
16. Impact of Sequencing Radiation Therapy and Chemotherapy on Long-term Local Toxicity for Early Breast Cancer: Results of a Randomized Study at 15 Year Follow up
Author: Paolo Pinnaro
Conference: ASTRO
17. Physician-driven variation in non-recommended imaging for women with early stage breast cancer
Author: A. N. Lipitz Snyderman
Conference: ASCO
18. Outcome analysis of patients with breast cancer and positive sentinel node
Author: A. Syed
Conference: IMPAKT
19. Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin containing neoadjuvant chemotherapy in patients witt TNBC: Results from GeparSixto
Author: G. Von Minekwitz
Conference:ASCO
20. Impact of neoadjuvant therapy on breast conservation rates in triple-negative and HER2 positive breast cancer: Combined results of CALGB 40603 and 40601 (Alliance)
Author: M. Golshan
Conference: ASCO
21. NRG Oncology/ RTOG 1014: 1 Year Toxicity Report From a Phase II Study of Repeat Breast Preserving Surgery and 3-D Conformal Partial-Breast Reirradiation (PBrl) for In-Breast Recurrence
Author: Douglas Arthur
Conference: ASTRO
22. Concordance of local and central HER2 status in 1597 patients participating in German neoadjuvant breast cancer studiesd 3-D Conformal Partial-Breast Reirradiation (PBrl) for In-Breast Recurrence
Author: B. Pftizner
Conference: IMPAKT
23. PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post menopausal women with hormone receptorpositive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy
Author: N.C. Turner
Conference: ASCO
24. Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance)
Author: M. N. Dickler
Conference: ASCO
25. Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomized trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV capecitabine (CAP) for HER2 negative locally recurrent/ metastatic breast cancer (LR/mBC)
Author: T. Brodowicz
Conference: ESMO
26. Radiotherapy plus trastuzumab in the treatment of Her2 positive locally advanced breast cancer
Author: A. Belokhvostova
Conference: IMPAKT
27. “High risk permenopausal luminal A breast cancer patients derive no benefit from adjuvant chemotherapy: results from DBCG77B randomized trial”
Author:Nielson TO
Conference: SABCS